General Anesthesia

Correct Answer

C — Volatile halogenated anesthetic agent

Rationale

Halothane is classified as a volatile halogenated anesthetic agent. It is a halogenated alkane that exists as a liquid at room temperature and vaporizes for delivery by inhalation. The term halogenated refers to the presence of fluorine, chlorine, and bromine atoms in its chemical structure. Intravenous anesthetic agents — such as propofol, etomidate, and ketamine — are administered by injection rather than inhalation. Inhaled anesthetic gases, such as nitrous oxide, are gaseous at room temperature and stored as liquids under pressure; they are physically distinct from volatile liquids that require vaporizers. Barbiturate anesthetic agents, such as thiopental, belong to the barbituric acid chemical class and are administered intravenously.

Correct Answer

A — Sevoflurane

Rationale

Sevoflurane is classified as the preferred agent for pediatric inhalational induction of anesthesia in high-resource settings. Its combination of low blood solubility (blood:gas partition coefficient approximately 0.65), a pleasant non-pungent odor, potent bronchodilation, and hemodynamic stability at induction doses makes it well suited for mask induction in children who do not yet have intravenous access. Desflurane is an airway irritant that provokes coughing, breath-holding, and laryngospasm at induction concentrations and is therefore not suitable for inhalational induction in any patient. Isoflurane has an intermediate blood:gas coefficient and a pungent odor that limits its use for inhalational induction. Halothane was the previous standard for pediatric inhalational induction but has been largely replaced by sevoflurane in high-resource settings because of its higher hepatotoxicity risk and catecholamine sensitization; it remains in use in low-resource settings where sevoflurane is unavailable.

Correct Answer

D — Inhaled anesthetic gas

Rationale

Nitrous oxide is classified as an inhaled anesthetic gas. Unlike the volatile halogenated agents — such as isoflurane, sevoflurane, desflurane, enflurane, and halothane — which are liquids at room temperature that require vaporizers to convert them into an inhalable vapor, nitrous oxide is a gas at room temperature and is stored as a liquid under pressure in cylinders. This physical distinction defines its classification. Intravenous anesthetic agents, such as propofol, etomidate, and ketamine, are administered by injection and do not require inhalational delivery. Barbiturate anesthetic agents, such as thiopental, are also administered intravenously and belong to the barbituric acid chemical class.

Correct Answer

B — Desflurane

Rationale

Desflurane has the lowest blood:gas partition coefficient of the volatile halogenated anesthetic agents, approximately 0.42. This means desflurane is the least blood-soluble of the halogenated agents, and its alveolar partial pressure rises most rapidly, producing the fastest induction and — more clinically relevant — the fastest and most predictable emergence of any halogenated agent. The rank order from lowest to highest blood:gas coefficient among the halogenated agents is: desflurane (approximately 0.42), sevoflurane (approximately 0.65), isoflurane (approximately 1.4), enflurane (approximately 1.9), and halothane (approximately 2.4). Halothane has the highest blood:gas coefficient and the slowest induction and emergence. Isoflurane and enflurane are intermediate. Nitrous oxide (approximately 0.47) has a similarly low coefficient but is a gas rather than a volatile halogenated agent and falls outside this halogenated agent ranking.

Correct Answer

A — Enflurane

Rationale

Enflurane is the only volatile anesthetic agent with clinically significant epileptogenic potential. This property was a primary reason for its displacement from clinical practice by isoflurane and sevoflurane. Isoflurane, sevoflurane, and desflurane do not have meaningful epileptogenic potential at clinical doses and are safe to use in patients with seizure disorders. Isoflurane at high doses produces burst suppression, which is an antiepileptiform pattern on electroencephalography. Halothane also lacks epileptogenic potential. Enflurane is therefore contraindicated in patients with seizure disorders — a distinction that separates it from all other agents in this class.

Correct Answer

C — Isoflurane

Rationale

Isoflurane is classified as the most widely used volatile anesthetic agent globally. Its favorable safety profile — minimal hepatotoxicity (approximately 0.2% hepatic metabolism), no catecholamine sensitization, no epileptogenic potential, and no nephrotoxic metabolites — combined with low cost and wide availability accounts for its global dominance. Sevoflurane has supplanted isoflurane for inhalational induction in high-resource settings and is preferred in patients with reactive airways disease, but isoflurane remains the global standard for maintenance. Halothane retains use in low-resource settings where isoflurane and sevoflurane may be unavailable. Desflurane offers the fastest emergence but requires a specialized heated vaporizer and is an airway irritant unsuitable for induction, limiting its use to specific clinical scenarios.

Correct Answer

B — Potentiation of gamma-aminobutyric acid type A receptor-mediated inhibitory chloride conductance

Rationale

The primary molecular mechanism of volatile halogenated anesthetic agents — including isoflurane, sevoflurane, desflurane, enflurane, and halothane — is potentiation of the gamma-aminobutyric acid type A receptor, a ligand-gated chloride ion channel that mediates inhibitory neurotransmission throughout the central nervous system. By enhancing chloride conductance and hyperpolarizing neurons, these agents suppress cortical and subcortical circuits responsible for consciousness. N-methyl-D-aspartate glutamate receptor antagonism is the primary mechanism of nitrous oxide and ketamine, which explains their distinct analgesic properties and different clinical profiles compared to the halogenated agents. Alpha-2 adrenergic receptor activation in the locus coeruleus is the mechanism of dexmedetomidine-induced sedation — a noradrenergic pathway entirely distinct from the gamma-aminobutyric acid type A system. Voltage-gated sodium channel blockade is the mechanism of local anesthetics and antiarrhythmic agents, not inhalational anesthetics.

Correct Answer

D — Halothane sensitizes the myocardium to catecholamine-induced arrhythmias, lowering the threshold for ventricular arrhythmias at epinephrine doses that would otherwise be safe

Rationale

Halothane sensitizes the myocardium to catecholamine-induced arrhythmias — a unique property not shared by modern volatile agents such as isoflurane, sevoflurane, or desflurane. In the presence of halothane, ventricular arrhythmias can occur at epinephrine doses that would be well tolerated under other anesthetic agents. This limits the safe use of epinephrine-containing local anesthetics during halothane-based anesthesia and is an important clinical distinction from modern agents. Halothane does not inhibit catecholamine metabolism; its arrhythmogenic effect is a direct myocardial pharmacodynamic property. Halothane does not block cardiac beta-1 adrenergic receptors — it directly suppresses sinoatrial node automaticity, causing bradycardia rather than tachycardia. The mechanism is myocardial sensitization, not a receptor blockade paradox or amplified chronotropy.

Correct Answer

A — Oxidative metabolism of halothane produces trifluoroacetyl chloride, which covalently binds liver proteins to form neoantigens that trigger an immune response on re-exposure

Rationale

Type II halothane hepatotoxicity is immune-mediated. Oxidative metabolism of halothane by the cytochrome P450 2E1 enzyme produces trifluoroacetyl chloride, a reactive intermediate that covalently modifies liver proteins. These trifluoroacetylated proteins are recognized by the immune system as foreign (neoantigens), and on re-exposure the immune response is amplified, producing fulminant hepatic necrosis with a high mortality rate. Re-exposure to halothane after a prior sensitizing exposure is therefore absolutely contraindicated. This mechanism is distinct from Type I halothane hepatotoxicity, which is a milder, self-limited enzyme elevation caused by reductive metabolism and direct hepatocyte toxicity in areas of relative hepatic hypoxia — the mechanism described in option B. Halothane does not inhibit cytochrome P450 2E1 — it is a substrate metabolized by this enzyme. Halothane does not activate hepatic stellate cells directly, and fibrosis is not the mechanism of halothane hepatitis.

Correct Answer

C — Nitrous oxide diffuses into the pleural air space faster than nitrogen exits, causing the pneumothorax to expand and potentially progress to tension physiology

Rationale

Nitrous oxide diffuses into air-filled body cavities approximately 34 times faster than nitrogen — the primary gas already present in those spaces — can leave. In a patient with a pneumothorax, nitrous oxide from the blood rapidly enters the pleural air space while nitrogen exits slowly. The net result is progressive expansion of the pneumothorax, which can convert a simple pneumothorax into a tension pneumothorax with mediastinal shift and cardiovascular collapse. This same mechanism produces clinically important contraindications for nitrous oxide in any closed gas-containing compartment: bowel obstruction (expansion of gas-filled bowel loops), pneumocephalus (expansion of intracranial air), intraocular gas bubbles (risk of acute glaucoma), and middle ear air spaces after tympanoplasty. Nitrous oxide does not inhibit hypoxic pulmonary vasoconstriction — that is a property of the volatile halogenated agents. Nitrous oxide does not react chemically with pleural fluid to produce nitrogen bubbles. Nitrous oxide mildly increases pulmonary vascular resistance through direct myocardial effects but this is not the mechanism of the pneumothorax contraindication.

Correct Answer

B — Nitrous oxide irreversibly oxidizes the cobalt ion of vitamin B12, inactivating methionine synthase and impairing deoxyribonucleic acid synthesis

Rationale

Nitrous oxide irreversibly oxidizes the cobalt ion of vitamin B12 (cobalamin), converting it from its active reduced form to an inactive oxidized form. Vitamin B12 in its active form is a required cofactor for methionine synthase, the enzyme that converts homocysteine to methionine and is essential for normal thymidylate synthesis and normal deoxyribonucleic acid synthesis. Inactivation of methionine synthase impairs deoxyribonucleic acid synthesis in rapidly dividing cells, producing megaloblastic anemia (a hematological syndrome of macrocytic red blood cells due to impaired cell division) and, with repeated or prolonged exposure, subacute combined degeneration of the spinal cord — a syndrome of demyelination in the dorsal and lateral columns identical to that seen with nutritional vitamin B12 deficiency. This mechanism explains why nitrous oxide must be avoided in patients with pre-existing vitamin B12 deficiency. Nitrous oxide does not inhibit vitamin B12 absorption in the ileum, block renal tubular reabsorption of vitamin B12, or directly demyelinate axons through lipid peroxidation.

Correct Answer

D — Desflurane stimulates pulmonary irritant receptors, triggering a transient sympathetic discharge that raises heart rate and blood pressure

Rationale

Desflurane is a significant airway irritant. When its inspired concentration is increased rapidly, it stimulates pulmonary irritant receptors in the airway, generating a reflex sympathetic surge that transiently raises heart rate and blood pressure. This effect is unique to desflurane among the modern volatile agents and is clinically important in patients with coronary artery disease or hypertensive heart disease, where sudden increases in myocardial oxygen demand may be poorly tolerated. Desflurane concentration should therefore be increased gradually in these patients. At stable maintenance concentrations, desflurane's cardiovascular profile is similar to isoflurane — peripheral vasodilation with relatively preserved cardiac output. Desflurane does not directly stimulate cardiac beta-1 adrenergic receptors. Desflurane does not sensitize the myocardium to catecholamines — that property is unique to halothane. Baroreceptor-mediated reflex tachycardia from vasodilation describes the hemodynamic profile of isoflurane and sevoflurane at stable concentrations, not the sympathetic surge seen with rapid desflurane concentration increases.

Correct Answer

A — Sevoflurane produces bronchodilation and is non-pungent, while desflurane is an airway irritant that can trigger bronchoconstriction

Rationale

All volatile halogenated agents produce some degree of bronchodilation through direct relaxation of bronchial smooth muscle, but sevoflurane is among the most potent bronchodilators and has a pleasant, non-pungent odor that does not provoke airway irritation. Desflurane, by contrast, is a significant airway irritant at induction and higher maintenance concentrations, commonly causing coughing, breath-holding, laryngospasm, and paradoxical bronchoconstriction in patients with reactive airways — making it unsuitable for this population. Sevoflurane's minimum alveolar concentration (approximately 2.0%) is higher than desflurane's (approximately 6 to 7%), not lower — so this property does not explain the selection. Sevoflurane undergoes more hepatic metabolism (approximately 3 to 5%) than desflurane (less than 0.02%), not less — and neither agent produces pulmonary metabolites relevant to bronchospasm. Sevoflurane's blood:gas partition coefficient (approximately 0.65) is actually higher than desflurane's (approximately 0.42), meaning desflurane equilibrates faster, not sevoflurane — so titration speed does not explain the preference in reactive airways.

Correct Answer

C — Emergence agitation with inconsolable crying, thrashing, and failure to recognize caregivers

Rationale

Emergence agitation — also called emergence delirium — is a clinically important adverse effect of sevoflurane that occurs particularly in young children, with peak incidence between ages 2 and 5. It presents as inconsolable crying, thrashing, disorientation, and failure to recognize caregivers in the immediate post-anesthetic period, typically resolving within 15 to 30 minutes without lasting harm. The mechanism is related to sevoflurane's rapid offset: the drug dissipates quickly from the central nervous system before full cortical reintegration occurs, producing a transient state of agitation. Effective prevention strategies include midazolam premedication, a small dose of propofol at emergence, fentanyl, adequate multimodal analgesia, and dexmedetomidine near the end of the procedure. Immune-mediated hepatitis from trifluoroacetylated neoantigens is a property of halothane, not sevoflurane, which follows a different metabolic pathway and does not produce trifluoroacetylated proteins. Catecholamine sensitization causing ventricular arrhythmias is unique to halothane among volatile agents. Epileptogenic cortical activity is characteristic of enflurane, not sevoflurane.

Correct Answer

D — Halothane sensitizes the myocardium to catecholamine-induced arrhythmias, lowering the threshold for ventricular arrhythmias at epinephrine doses that would be safe under other anesthetic agents

Rationale

Halothane sensitizes the myocardium to catecholamine-induced arrhythmias — a unique adverse property not shared by modern volatile agents such as isoflurane, sevoflurane, or desflurane. In the presence of halothane, ventricular arrhythmias can be triggered by epinephrine concentrations that would be well tolerated under other anesthetic agents. This property limits the safe use of epinephrine-containing local anesthetics during halothane-based anesthesia and is a key clinical distinction from all modern volatile agents. Halothane does not inhibit hepatic metabolism of epinephrine; the arrhythmia results from a direct myocardial pharmacodynamic effect, not from elevated epinephrine plasma levels. Halothane does not block cardiac potassium channels in the manner that produces QT prolongation; its arrhythmogenic mechanism is myocardial catecholamine sensitization. Epinephrine does not interact with gamma-aminobutyric acid type A receptors; the myocardium does not have anesthetic-binding sites of this type.

Correct Answer

B — Nitrous oxide, because it diffuses into the intraocular gas bubble faster than sulfur hexafluoride exits, causing the bubble to expand and raising intraocular pressure

Rationale

Nitrous oxide diffuses into air-filled and gas-filled body cavities far faster than the gases already present can exit, causing progressive expansion of those spaces. When intraocular sulfur hexafluoride or perfluoropropane gas tamponade is present after vitreoretinal surgery, nitrous oxide rapidly enters the bubble, expanding it and raising intraocular pressure to levels that can cause acute angle-closure glaucoma and permanent vision loss. This contraindication persists for weeks after surgery until the intraocular gas is fully reabsorbed — the exact duration depends on the gas used and bubble size. Sevoflurane is not contraindicated here; compound A nephrotoxicity from low fresh gas flow anesthesia has not been demonstrated clinically and is unrelated to intraocular structures. Isoflurane does not expand intraocular gas; its peripheral vasodilation does not alter intraocular pressure through this mechanism. Desflurane's airway-irritant properties are a concern for induction, but airway-triggered Valsalva is not a recognized mechanism of intraocular gas expansion.

Correct Answer

A — Sevoflurane, because it is non-pungent, produces bronchodilation, and is hemodynamically stable at induction doses

Rationale

Sevoflurane is the agent of choice for pediatric inhalational induction. Its non-pungent, pleasant odor avoids the breath-holding and agitation that pungent agents cause in children inhaling through a mask. Its relatively low blood:gas partition coefficient (approximately 0.65) allows alveolar partial pressure to rise quickly, producing smooth and reasonably fast induction. It is a potent bronchodilator and is hemodynamically stable at induction doses, minimizing the risk of laryngospasm or cardiovascular depression. Desflurane is unsuitable for inhalational induction in any patient — its pungent, irritating odor reliably causes coughing, breath-holding, laryngospasm, and bronchospasm at induction concentrations, despite having the lowest blood:gas coefficient of the halogenated agents. Isoflurane has a pungent odor that limits its acceptability for mask induction, particularly in children. Halothane's high potency (low minimum alveolar concentration) means less vapor is needed, but it has been largely replaced by sevoflurane in high-resource settings due to its catecholamine sensitization and immune-mediated hepatitis risk; in this context sevoflurane is the preferred choice.

Correct Answer

C — The first halothane exposure sensitized the immune system to trifluoroacetylated liver proteins; the second exposure regenerated these neoantigens and triggered an amplified immune attack on hepatocytes

Rationale

Type II halothane hepatotoxicity is immune-mediated and requires prior sensitization. During any halothane exposure, oxidative metabolism by cytochrome P450 2E1 produces trifluoroacetyl chloride, which covalently modifies liver proteins to form trifluoroacetylated neoantigens. On a first exposure, this may generate sensitization without overt hepatitis. On re-exposure, the same trifluoroacetylated neoantigens are regenerated and recognized by the primed immune system, triggering a rapid and amplified immune response that produces fulminant hepatic necrosis — a condition carrying high mortality. This mechanism explains why re-exposure to halothane after a prior exposure is absolutely contraindicated and why the syndrome occurs on the second, not first, exposure. Option A describes Type I halothane hepatotoxicity — a mild, self-limited enzyme elevation from reductive metabolism and direct hepatocyte injury in hypoxic zones, which does not cause fulminant hepatic failure. Halothane does not accumulate in fat stores and then release in toxic concentrations — its hepatotoxicity on re-exposure is immunological, not pharmacokinetic. Halothane is a substrate for cytochrome P450 2E1, not an inhibitor of it.